EP05.02-016 Aumolertinib after Adjuvant Chemotherapy/Radiotherapy in Stage pIIIA-N2 Non-Small-Cell Lung Cancer with EGFR Mutation

Abstract

Several trials such as the ADJUVANT, ADAURA, EVAN, EVIDENCE, and SELECT have been confirmed that epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeting adjuvant therapy provides a dramatic response to patients with EGFR-mutation non-small cell lung cancer (NSCLC). Especially compared with stage II, patients with pIIIA-N2 may be the precise population for the clinical benefit of adjuvant targeted therapy. A number of multi-center, large-sample retrospective studies have evaluated that adjuvant chemotherapy/radiotherapy can also improve the local control rate and survival rate of pIIIA-N2 NSCLC.